Abstract
Purpose
p53 and Ki67 status can be relevant to the management of glioblastoma. The goal of this study is to determine whether tumor morphology and bulk depicted on MRI correlate with p53 and Ki67 in glioblastoma.
Methods
A retrospective review of 223 patients with glioblastoma and corresponding p53 or Ki67 status, along with T1-weighted post-contrast MR images was performed. Enhancing tumors were outlined for determining surface regularity, tumor bulk, and necrotic volume. The median value of 0.1 was chosen for p53 and 0.2 for Ki67 to separate each data set into two classes. T tests and receiver operating characteristic analysis were performed to determine the separation of the classes and the predicting power of each feature.
Results
There were significant differences between tumor surface regularity (p = 0.01) and necrotic volume (p = 0.0429) according to Ki67 levels, although neither had statistically significant predictive power (AUC = 0.697, p = 0.0506 and AUC = 0.577, p = 0.164, respectively). There were also significant differences between tumor bulk (p = 0.0239) and necrotic volume (p = 0.0200) according to p53 levels, but again no significant predictive power was found using ROC analysis (AUC = 0.5882, p = 0.0894 and AUC = 0.567, p = 0.155, respectively).
Conclusion
Quantitative morphological tumor characteristics on post-contrast T1-weighted MRI can to a certain degree provide insights regarding Ki67 and p53 status in patients with glioblastoma.
Similar content being viewed by others
References
Olar A, Aldape KD (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232:165–177
Touat M, Idbaih A, Sanson M, Ligon KL (2017) Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol 28:1457–1472
Bosnyák E, Michelhaugh SK, Klinger NV, Kamson DO, Barger GR, Mittal S, Juhász C (2017) Prognostic molecular and imaging biomarkers in primary glioblastoma. Clin Nucl Med 42:341–347
Zhang Y, Dube C, Gibert M Jr (2018) The p53 pathway in glioblastoma. Cancers (Basel)10 pii: E297
England B, Huang T, Karsy M (2013) Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol 34:2063–2074
Schröder R, Feisel KD, Ernestus RI (2002) Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas. J Neuro-Oncol 56:127–132
de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504–1513
Pérez-Beteta J, Molina-García D, Ortiz-Alhambra JA, Fernández-Romero A, Luque B, Arregui E, Calvo M, Borrás JM, Meléndez B, Rodríguez de Lope Á, Moreno de la Presa R, Iglesias Bayo L, Barcia JA, Martino J, Velásquez C, Asenjo B, Benavides M, Herruzo I, Revert A, Arana E, Pérez-García VM (2018) Tumor surface regularity at MR imaging predicts survival and response to surgery in patients with glioblastoma. Radiology 288:218–225
Grossmann P, Gutman DA, Dunn WD Jr, Holder CA, Aerts HJ (2016) Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in glioblastoma. cBMC Cancer 16:611
Dechristé G, Fehrenbach J, Griseti E, Lobjois V, Poignard C (2018) Viscoelastic modeling of the fusion of multicellular tumor spheroids in growth phase. J Theor Biol 454:102–109
Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN, Cancer Genome Atlas Research Network (2010) An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17:98–110
Balogh GA, Mailo D, Nardi H et al (2010) Serological levels of mutated p53 protein are highly detected at early stages in breast cancer patients. Exp Ther Med 1:357–361
Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neuro-Oncol 27:65–73
Rios Velazquez E, Meier R, Dunn WD Jr et al (2015) Fully automatic GBM segmentation in the TCGA-GBM dataset: prognosis and correlation with VASARI features. Sci Rep 5:16822
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work is supported, in part, by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health under Grant no. T32 EB002103.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
For this type of study formal consent is not required.
Informed consent
For this type of study formal consent is not required.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hasse, A., Dapash, M., Jeong, Y. et al. Correlation of post-contrast T1-weighted MRI surface regularity, tumor bulk, and necrotic volume with Ki67 and p53 in glioblastomas. Neuroradiology 61, 861–867 (2019). https://doi.org/10.1007/s00234-019-02204-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00234-019-02204-1